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Improved Generation of Anti-Tumor Immunity by Antigen Dose Limitation 
Joshua D. Shofner.  Department of Dermatology, Yale University School of Medicine, 
New Haven, Connecticut 
 
The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic 
peptides derived from the clonal T cell receptor (TCR) providing an attractive model for 
refinement of anti-tumor immunization methodology.  To produce a clinically 
meaningful anti-tumor response, induction of cytotoxic anti-CTCL cells must be 
maximized while suppressive T regulatory cells (Treg) should be minimized.  We have 
demonstrated that engulfment of apoptotic CTCL cells by dendritic cells (DC) can lead to 
either CD8 anti-CTCL responses or immunosuppressive Treg induction.  Treg generation 
is favored when the number of apoptotic cells available for ingestion is high.   In this 
study, we sought to determine whether the balance between immunity and 
immunosuppression could be shifted towards a CD8 anti-CTCL response by lowering the 
ratio of apoptotic CTCL cells available for DC ingestion.  CTCL cell apoptosis was 
produced by engagement of the TCR by anti-CD3 antibody affixed to magnetic beads. 
The physical perturbation inherent in passage through a separation column induced 
monocytes to differentiate into DC, demonstrated by increased expression of class II and 
CD86 and decreased expression of the monocyte marker CD14.  The immature DC 
internalized and processed apoptotic CTCL cells and could potentially present the tumor-
derived peptides in the context of MHC class I and II.  As the number of apoptotic cells 
increased, there was a dose-dependent increase in the expression of Treg markers CTLA-
4, CD25, and FoxP3, with a ratio of apoptotic cell/DC loading of >10:1 corresponding to 
the greatest Treg induction.  These inducible phenotypic Treg also functionally inhibited 
CD8-mediated perforin expression in vitro.  At lower levels of apoptotic cell/DC loading 
of <5:1, there was an expansion of the CD8 T cell compartment with increased perforin 
expression and increased CTCL cell death, indicating anti-tumor activity.   These 
findings demonstrate that the ratio of apoptotic cells supplied to DC is an important 
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Cutaneous T cell lymphoma (CTCL) is an umbrella designation that unifies a diverse 
group of clinical presentations on the basis of histopathologic and immunologic criteria.   
CTCL, so named over thirty years ago to unite the diverse clinical presentations of 
malignant CD4+ T cells that migrate to the skin [1], is now recognized as a clonal 
proliferation of epidermotropic T cells that uniformly carry a common T cell receptor 
(TCR) and also display cell surface expression of a memory (CD45RO+), inducer (CD4+),  
and cutaneous homing leukocyte antigen (CLA+) phenotype [2-4].  
 
Our initial understanding of the malignancy began in the early 1970’s, when researchers 
discovered that Sezary syndrome, a known entity consisting of erythroderma and 
abornmal circulating leukocytes with cerebriform nuclei, was in fact a proliferation of T 
cells [5].  Following this discovery, work by Edelson et al demonstrated that the tissue-
infiltrating lymphocytes of mycosis fungoides (MF), also a well known entity at the time, 
were also of T cell origin [6].  The observation that these patients occasionally developed 
into Sezary syndrome led to the notion that the two diseases may in fact be part of a 
single spectrum of cutaneous lymphoma.  Fast forward to today, and our understanding 
has grown by leaps and bounds.  The clonality of these malignant T cells has been 
confirmed at the phenotypic and molecular level by the demonstration that the CTCL 
cells all carry an identical TCR, and karyotype and polymerase chain reaction analysis 
have revealed clonal abnormalities unique for individual patients [7-9].  Initially the 
tumor cells localize in the skin of afflicted patients, surrounding Langerhans cells that 




become more poorly differentiated and often spread hematogenously throughout the body 
as a leukemia, forecasting a much poorer prognosis.  It is the early epidermal focus of 
malignant T cells surrounding a central Langerhans cell [11], an immature member of the 
dendritic cell (DC) series [12], that is the diagnostic hallmark of the disease, the Pautrier 
microabscess [3], which is shown in Figure 1 [13]. 
 
 
Figure 1. Pautrier Microabscess 
 
Clinical Presentation 
CTCL can present in a variety of complex ways, from the classic patch or plaque lesions 
associated with MF to the generalized erythema typically associated with Sezary 
syndrome.  In addition to the more common presentations, alternate ones may be seen as 
well, including an eczematous form characterized by persistent, nonspecific, flat, red, 
pruritic eczematous plaques and a tumor stage form, which develops from pre-existing 
plaques or erythroderma.  The more indolent forms of the disease are often so gradual in 




years until a definitive diagnosis can be made [14].  Since the clinical presentation of the 
malignancy depends upon the dominant subclone of the malignant T cell population 
present, there tends to be a wide spectrum of clinical presentation.  Given this variability  
in presentation for cutaneous lymphoma, there are now two major classification systems 











Given the subtle and often insidious manner in which CTCL often presents, a diagnosis is 
usually made through a combination of clinical, histologic, and immunologic criteria.  
Biopsies should be taken from multiple lesions on the patient to ensure more accurate 
diagnosis.  Histologically, one can often recognize the classic Pautrier microabscess in a 
certain cases, as shown in Figure 1, but more often can visualize lymphocytic infiltration 
of the superficial dermis with individual migration of lymphocytes among keratinocytes.  
This individual migration of atypical lymphocytes is characteristic of the 
epidermotropism of the malignancy [13, 15].  As described earlier, the natural 
progression of the malignancy involves progressive degrees of de-differentiation, which 
leads to the eventual loss of the epidermotropism that was once characteristic of the 
diseasee.  Once the disease has sufficiently undifferentiated and has become leukemic, 
diagnostic techniques can be expanded to include flow cytometric analysis of peripheral 
blood to look for the clonal TCR Vβ family, increased CD4:CD8 T cell ratio, and loss of 
the CD26 receptor [16-19].  Each of these techniques – clinical, histologic, and 
immunologic – must be used in concert to make the most accurate diagnosis possible for 
the malignancy.   
 
Normal Immunology  
While CTCL remains a relatively rare disorder, with the latest incidence rates of 
approximately 0.36 per 100,000 person-years [20, 21], it remains an excellent model for 
investigators interested in furthering their understanding of the mechanisms of immune 




the unique ability to investigate a malignancy of a prime player in the body’s immune 
system.  It has provided insight into the clinical manifestations of T cell dysfunction, and 
has led to remarkable discoveries regarding the relationship between T cells and antigen-
presenting cells of the immune system.   These discoveries have had wide-reaching 
effects and are applied to a number of other T cell mediated processes, including graft-
versus-host disease and psoriasis.   
 
In normal human immunity, the skin serves as a first line of defense against the external 
environment, protecting the body from chemical, microbial, and thermal agents, as well 
as playing a key role in hydration status and maintenance of a constant body temperature.  
Disruption of this vital organ can lead to serious consequences, including invasion by 
environmental pathogens.  The human immune system plays the most notable role in 
protecting us from pathogenic invasion.  Immunologically, this is accomplished through a 
complex system of T cells and antigen-presenting cells/dendritic cells (APC/DC), which 
are constantly circulating throughout the body.  The role of the professional antigen-
presenting cell is to phagocytose and process exogenous antigen and then present this 
antigen to the TCR of circulating T cells.  The T cell receptor is a complex of 
heterodimeric proteins encoded by a set of four genes that recombine to form a diverse 
population of circulating TCR [22].  This almost limitless population of diverse TCR 
allows for the unique specificity that makes the adaptive immune response so effective.  
As circulating naïve T cells circulate throughout the bloodstream, they encounter their 
specific antigen presented on the surface of a mature dendritic cell.  Mature DC that have 




Once the circulating T cells encounter antigen displayed in the context of MHC class I 
and II in the peripheral lymphoid tissue, they proliferate and differentiate into antigen-
specific effector cells [22, 23].  The presentation of antigen to naïve T cells is essential 
for the generation of a T cell response, and is accomplished by the process and antigen 
processing and presentation.  
 
The effector cells of the immune system, T cells, are a population of leukocytes of the 
adaptive immune system that are defined by their expression of either CD4 or CD8 
accessory molecules.  CD4+ T cells comprise the helper T cell subset and promote B cell 
immunoglobulin production and can stimulate effector CD8+ T cell function [24, 25].  
CD8+ T cells are stimulated by peptides displayed in class I MHC molecules on antigen-
presenting cells and can mediate their tumor cytolysis through production of cytokines 
such as TNF-α and the secretory granules perforin and granzymes [26].   
 
Dendritic cells have assumed a central role in orchestrating both immunity and tolerance.  
One key component of the type of immune response generated appears to be the 
maturation status of the dendritic cell.  Immature DC are aggressively phagocytic and 
serve as sentinels, surveying the bloodstream for foreign invaders.[12, 27]  Mature DC 
up-regulate molecules that present antigen to the effectors cells of the immune system, 
namely class I and II major histocompatibility antigens, and display co-stimulatory 
molecules that enhance the immune response. [12]  DC that present foreign peptides in 
the context of high levels of co-stimulatory molecules such as CD80 and CD86 to naïve 




present self peptide can induce T regulatory (Treg) cells and tolerance [28].  This 
complex relationship between DC and presentation of antigen to naïve and memory T 




Figure 3.  Relationship between DC maturation status and induction of immunity or 
tolerance.   
 
T regulatory cells have been recently identified as CD4+, CD25+ T cells that inhibit 
immune responses, prevent autoimmune disease, and maintain transplant tolerance [29, 
30].  At least two types of Treg are currently recognized, those that are thymus-derived 




T cell compartment [29].  There are a number of cell surface markers currently used to 
characterize the Treg population, including the α-chain of the IL-2 receptor (CD25), the 
inhibitory member of the co-stimulatory family cytotoxic T lymphocyte antigen-4 
(CTLA-4), glucocorticoid-induced TNF receptor (GITR), and the forkhead transcription 
factor, FoxP3.  Treg cells are anergic and do not proliferate in response to TCR 
stimulation [31, 32].  The mechanism of Treg cell suppression remains controversial and 
appears to vary based on the culture conditions and the immunosuppression model 
investigated [33].  Several models have described secretion of inhibitory cytokines as 
well as direct cell contact possibly mediated through CTLA-4 engagement of B7-1 and 
B7-2 on the APC.  CD25-mediated depletion of the supportive cytokine IL-2 may also 
serve to inhibit immune responses [34].  Given the association of T regulatory cells with 
a number of malignancies, including melanoma, lung, ovarian, pancreatic, and breast 
cancer, they may play a role in suppressing anti-tumor immune responses and help to 
perpetuate the malignancy [35-37]. 
 
Immunology in CTCL 
In CTCL, the tumor cells lack the co-stimulatory molecules required to trigger an 
immune response, which contributes to their ability to evade induction of anti-tumor 
immunity and thus, persist and disseminate.  Despite the role of DC in providing 
proliferative support for the malignancy, DC immunotherapy has demonstrated clinical 





We have recently found that passage of cells from CTCL patients through an anti-CD3 
magnetic bead column can achieve the simultaneous induction of apoptosis in the 
malignant T cell population and differentiation in the monocyte population creating, after 
overnight culture, a population of tumor-loaded DC capable of initiating an immune 
response in vitro [40].  This column-based method of generating tumor-loaded DC 
utilizes the mechanistic principles discovered in extracorporeal photopheresis (ECP), 
shown below in Figure 4, the first FDA-approved immunotherapy for cancer [41].  
Clinical trials of ECP have shown response rates of 73% in late stage CTCL patients with 
an extremely safe side effect profile [42].  ECP has been recently modified by the 
addition of an overnight incubation step.  The new procedure has been termed 
“Transimmunization”, wherein malignant T cells were rendered apoptotic by ultraviolet 
A (UVA) light photo-activated 8-methoxypsoralen (8-MOP) and were avidly engulfed by 
immature DC, whose transition from monocytes was triggered by the physical 
perturbation produced when the cells were passed through the UVA exposure plate of the 
ECP apparatus.  In Transimmunization, the transitioning DC and the apoptosing 
leukocytes are co-cultivated overnight to permit engulfment of the apoptotic cells and 
subsequent processing and presentation of the tumor-derived peptides prior to re-infusion 





Figure 4.  Mechanism of extracorporeal photopheresis 
 
We have previously shown that when CTCL cells encounter autologous DC loaded with 
high numbers of apoptotic cells, they adopt the phenotype and function of T regulatory 
(Treg) cells, expressing high levels of the Treg markers CTLA-4, CD25, and FoxP3, as 
well as secreting interleukin-10 (IL-10) and transforming growth factor-β (TBF- β) and 
suppressing normal T cell antigen driven secretion of interleukin-2 (IL-2) and interferon-
γ (IFN-γ) [10].  The induction of Treg from responding CTCL cells may be hindering the 
effectiveness of existing immunotherapies for CTCL, and understanding the mechanism 





In these experiments, we sought to determine if the level of apoptotic cell loading 
controlled the balance between the development of an anti-tumor immune response and 
immunosuppressive Treg cell generation.  We found that when lower numbers of 
apoptotic cells were processed by DC, a CD8 T cell response could be stimulated while at 
higher levels of apoptotic cell up-take by DC we could induce CTCL cell Treg 








































Statement of Purpose 
 
In this study, our aim was to further understand the role that antigen dose plays in the 
generation of an immunostimulatory response versus a suppressive response.  Having 
previously demonstrated that autologous DC loaded with large number of apoptotic 
CTCL cells can induce tolerance in responding autologous CTCL cells, we sought to 
determine if that balance could be shifted toward the generation of immunity by lowering 
the dose of apoptotic cells processed by the DC.  More specific aims include the favoring 
the induction of T regulatory cells and demonstration of Treg specific markers following 
co-culture of responding CTCL cells with autologous DC that have engulfed large 
numbers of apoptotic cells using the column based method described in the Methods 
section  In addition, we sought to determine if by lowering the number of apoptotic 
malignant T cells engulfed by the DC, could we achieve decreased expression of Treg 
markers and increased T cell death and increased perforin expression, indicating 































































Patient Population:  Specimens were obtained from a leukapheresis harvest of CTCL 
patients (in accordance with the guidelines of the Yale human investigation committee) 
undergoing treatment with standard ECP.  All patients had advanced disease with clonal 
CD4+ T cell populations present in the peripheral circulation as determined by 
immunophenotyping with antibodies to the clonotypic variable region of family-specific 
TCR or polymerase chain reaction to detect rearrangements of the beta or gamma chain 
of the TCR as well as CD8 T cell compartments >10% of the circulating lymphocyte 
population. 
Cell Isolation:  On Day 0, peripheral blood mononuclear cells (MNL) were isolated from 
the leukapheresis harvest by centrifugation over a ficoll-hypaque gradient followed by 
two washes in RPMI 1640 (Gibco, Gaithersburg, MD) containing 10% AB serum and 2 
mM EDTA.  An aliquot of the MNL was then isolated, purified, and cultured for 
subsequent re-addition on Day 1.    Within this aliquot, CD4+ and CD8+ cells were 
column-purified using 40 μl Macs α-human CD4 and CD8 microBeads (Miltenyi 
Bioteck, Auburn CA) according to manufacturer’s instructions.  The enriched CD4+ and 
CD8+ T cells (>97%±0.5% CD4+ and >98%±0.5% CD8+, respectively) were suspended 
in RPMI 1640 with 15% autologous serum and IL-2/IL-7 and cultured individually in 
separate wells of a 12 well tissue culture plate (Falcon).  Another aliquot of the Day 0 
isolated MNL was reserved to construct the apoptotic cell and DC dose response curves, 
and controls.  MNL (2 x 107) from the leukapheresis harvest were incubated with 40 μl 




described [9], CTCL cell binding to CD3 antibody rendered the malignant T cells 
apoptotic.  As a control, another portion of MNL (2 × 107) was incubated with 40 μl 
Macs α-human CD4 microBeads.  Following the twenty minute incubation, the cells were 
passed through the magnetic bead column, allowing separation of the MNL into either 
CD3+ and CD3- fraction or CD4+ and CD4- fractions.   The CD3-treated and CD4-
treated cells were then cultured in 3 ml RPMI 1640 containing 15% AB serum.  In some 
experiments, increasing doses of CD3-treated cells were added to 105 autologous DC 
obtained from the column eluate to create the dose response curves.  Controls consisted 
of increasing doses of CD4-treated CTCL cells added to 105 autologous DC.    
On Day 1, the individually cultured column-purified CD4 and CD8 cells (106) were 
added to the CD3-treated apoptotic cell-loaded DC as well as the CD4-treated control 
population.  After a second overnight culture, the cells were harvested, counted, and 
immunophenotyped for markers of T cells, DC, Tregs, and apoptotic cells.  I directly 
participated in all of these experiments.   
Immunophenotyping:  In order to monitor enrichment of the purified CD4+ and CD8+ 
cell populations and to measure the effect of loading DC with differing number of 
apoptotic malignant T cells, the cells were stained by two-color immunofluorescence 
with a panel of antibodies to monocytes, DC, Tregs, and cytotoxic T cells.  Cells (1 × 106) 
were incubated with 10–20 μl of fluorochrome conjugated monoclonal antibody for 30 
minutes in the dark at 4°C. The antibodies were directly conjugated to fluorescein (FITC) 
or phycoerythrin (PE) and included: CD3-FITC (pan T cell); CD4-FITC (inducer T cell); 




HLA-DR-FITC (anti-class II MHC molecule) and CD86-PE (B7.2 co-stimulatory 
molecule) and their isotype controls.  Cells were washed once and suspended in PBS and 
read on a FC500 flow cytometer (Beckman Coulter) within 24 hours.    
 
Combined membrane and cytoplasmic staining was performed following manufacturers 
instructions for cell fixation and permeabilization (Intraprep kit, Beckman Coulter). 
Antibody combinations included: membrane CD4-FITC/cytoplasmic CTLA4-PE 
(inhibitory member of the co-stimulatory family); membrane CD3-FITC/cytoplasmic 
CTLA4-PE; membrane CD4-FITC/cytoplasmic FoxP3 (inhibitory transcription factor); 
membrane CD3-FITC/cytoplasmic Apo2.7-PE (apoptotic cells); membrane CD8-
FITC/cytoplasmic perforin-PE (cytotoxic granule); and isotype controls (Beckman 
Coulter).  Data was analyzed using the CXP software (Beckman Coulter).  Cell staining 
was conducted by myself, Nianci Wang, and Minjie Wu.  All data analysis was done my 
myself of Gabe Vasquez with the help of Dr. Carole Berger.   
Statistical Evaluation:  The expression of DC markers and the induction of a Treg or 
cytotoxic T cell response were evaluated statistically in 3 to 5 replicate cultures by the 
student’s t test, or if the data was not normally distributed, by the Mann-Whitney Rank 






















CTCL Cells Rendered Apoptotic by CD3 Antibody Binding      
MNL including monocytes and CTCL cells obtained from a leukapheresis harvest of 
CTCL patients were passed through an anti-CD3 magnetic bead column to induce 
apoptosis in the antigen-experienced CTCL cells and were then co-cultured with column-
passaged monocytes.  As a control, an aliquot of the leukocytes was passed through an 
anti-CD4 magnetic bead column, and these viable CTCL cells were cultured with 
autologous DC in the same manner as the apoptotic T cells.  In Figure 1, apoptosis was 
determined by measurement of the co-expression of the membrane T cell marker CD3 
and cytoplasmic expression of the early apoptotic marker APO2.7.  On primary Day 0 
isolation, the percentage of CD3+ cells expressing the apoptotic marker APO2.7 was 
0.646%.  After overnight culture, 6.96% of the T cell population bound to anti-CD4 
antibody-conjugated beads was apoptotic.  When lymphocytes were treated with CD3 
antibody-conjugated beads, a 2.96-fold increase (P≤ 0.001) in the percentage of apoptotic 
T cells was found (20.576%).  Thus, CTCL cells treated with anti-CD3 antibody were 
rendered apoptotic at a significantly higher percentage and are termed apoptotic CTCL 
cells for all future experiments.  Those CTCL cells treated with anti-CD4 antibody had a 
significantly higher percentage of viable cells and are denoted as viable for the remainder 







Passage of Monocytes through Magnetic Column Induces DC differentiation 
Apoptotic CTCL cells were co-cultured with column-passaged monocytes and markers 
known to be up regulated during DC differentiation [43] were analyzed after overnight 
culture to determine the ability of passage through the magnetic bead column to drive the 
evolution of the monocyte population into DC.  Monocyte differentiation into immature 
DC was measured by monitoring changes in expression of the monocyte marker, CD14, 
 Figure 1.  Induction of CTCL cell apoptosis by binding to anti-CD3 antibody. 
CTCL cells were incubated with either anti-CD4 or anti-CD3 antibody and cultured 
overnight with column-passaged monocytes.  Apoptosis was determined by measuring 
co-expression of the T cell marker, CD3, and the early apoptotic marker, APO2.7.   






and DC markers, class II and CD86.  Loss of CD14 expression was revealed by a 
decrease in the mean fluorescent intensity (MFI) of the CD14 fluorochrome from primary 
isolation on Day 0 followed by co-culture with viable CTCL cells.  The maximum 
reduction in CD14 MFI was found when column-passaged monocytes were co-cultured 
with CTCL cells rendered apoptotic by CD3 antibody (Fig 2A).  A 43% reduction of 
expression of the monocyte marker CD14 was found in comparison to the level expressed 
on monocytes isolated on Day 0 (P≤ 0.005).  There was no significant difference in the 
reduction in CD14 expression between differentiating DC cultured with viable CTCL 
cells or apoptotic CTCL cells.  However, the addition of apoptotic tumor cells enhanced 
the decrease in CD14 expression while the presence of viable CTCL cells was not as 
effective in stabilizing the monocyte to DC conversion. 
 
In addition, expression of class II and CD86 increased significantly (P< 0.017-P< 0.029 
respectively) upon co-culture with column-differentiated DC fed apoptotic CTCL cells as 
compared to Day 0 controls.  Class II expression increased from the level found on Day 0 
monocytes to an intermediate increase found on the transitioning immature DC that had 
been co-cultured with viable CTCL cells (P≤ 0.011) to the maximal increase seen when 
apoptotic CTCL cells (Fig. 2B) were co-cultured with the immature DC.   A 5.5-fold 
increase in class II expression was found when the DC were fed apoptotic CTCL cells 
and compared to the monocytes isolated on Day 0.  Expression of the co-stimulatory 
molecule CD86 also increased from day 0 to the intermediate increase found on 
transitioning immature DC that had been co-cultured with viable CTCL cells (P≤ 0.029) 




in CD86 expression was found when DC that had engulfed apoptotic cells were 
compared to monocytes tested on primary isolation.  Therefore, passage of CTCL cells 
through an anti-CD3 magnetic bead column and subsequent co-culture of newly 
apoptotic CTCL cells with column activated monocytes generated significantly enhanced 
DC differentiation.  Co-culture of column-activated monocytes with viable CTCL cells 
was also effective in generating immature DC but the addition of apoptotic CTCL cells 




















 Figure 2.  DC differentiation from monocytes induced by column passage and apoptotic 
CTCL cell loading.   
     DC and apoptotic CTCL cells were co-cultured following passage of MNL through an 
anti-CD3 magnetic bead column.  DC differentiation was monitored by measuring 
expression of cell surface markers using a flow cytometer gated on the monocyte 
population.  A.  Significant decrease in expression of monocyte marker CD14 was found 
on column-passaged monocytes co-cultured with apoptotic CTCL cells when compared 
to the level identified on Day 0 monocytes. B. Significant increase in expression of class 
II was found on column-passaged monocytes co-cultured with apoptotic CTCL cells 
when compared to the level identified on Day 0 monocytes. C. Significant increase in the 
expression of CD86 was found on column-passaged monocytes co-cultured with 
apoptotic CTCL cells when compared to the level identified on Day 0 monocytes 
Statistical analysis performed with student’s t test or Mann Whitney Rank-Sum Test.  






Induction of a Treg phenotype.  
Freshly purified CTCL cells were incubated overnight with DC that had ingested large 
numbers of apoptotic CTCL cells using an apoptotic CTCL cell to DC ratio of ≥ 10:1.  A 
portion of the responding CTCL cell population adopted the phenotype of T regulatory 
cells, expressing the cell surface marker CD25 and the cytoplasmic markers CTLA-4 and 
FoxP3.  CTLA-4 was up regulated in the cytoplasm of CTCL cells exposed to autologous 
DC that had engulfed large numbers of apoptotic cells (Fig. 3C), as compared to the 
control group (Fig. 3B) and the primary day 0 isolate (Fig 3A).  CTCL cell membrane 
expression of CD25 increased upon co-culture with autologous DC that had engulfed 
large numbers of apoptotic CTCL cells (Fig 3E) as compared to controls (Fig. 3D).  The 
viable CTCL cells were also partially activated to express increased membrane CD25 
(Fig 3D), but not other markers of Treg conversion (Fig 3B & F).  Cytoplasmic 
expression of FoxP3 increased 13.9-fold following incubation with autologous DC that 
had engulfed large numbers of apoptotic cells (Fig. 3G) as compared to the control 
population (Fig. 3F).  Thus, by co-culturing freshly purified CTCL cells with autologous 
DC that have engulfed large numbers of apoptotic CTCL cells, the responding CTCL 






Figure 3.  Induction of a T regulatory phenotype in CTCL cells.   
A. Untreated Day 0 CTCL cells were stained for co-expression of CD4 on the cell  
surface and CTLA-4 in the cytoplasm.  DC were fed viable CTCL in ratio of >10:1 or 
apoptotic CTCL cells in ratios that exceeded 10 viable (B, D, & F) or apoptotic CTCL 
cells (C, E, & G):1 DC and co-expression of: B & C membrane CD4 and cytoplasmic 
CTLA4; D & E membrane CD4 and membrane CD25; or F & G cytoplasmic expression 
of FoxP3.   
 
We performed a dose response curve by adding increasing numbers of CTCL cells that 
had been rendered apoptotic by incubation with CD3-antibody conjugated to magnetic 
beads to overnight cultures of column-generated transitioning DC.  We found that in the 




of responding CTCL cells that expressed CTLA-4 increased as the number of apoptotic 
cells available for DC ingestion in the co-culture increased (Fig 4A).  A dose of 0.3 x 106 
apoptotic cells fed to 105 DC induced only 4.88% of the freshly added CTCL cells to 
express cytoplasmic CTLA-4.  As the dose of apoptotic CTCL cells rose to 1.5 x 106 and 
3.0 x 106, the percentage of freshly added CTCL cells expressing CTLA-4 increased to 
12.83% and 18.6% respectively.  In contrast, as a control, addition of increasing numbers 
of viable CTCL cells to the constant number of DC did little to enhance the percentage of 
CTCL cells expressing CTLA-4.  In addition, as the dose of apoptotic cells fed to a 
constant number of DC increased, the percentage of CD4+ T cells expressing FoxP3, the 
phenotypic hallmark of Tregs, increased as well (Fig. 4B).  At 0.1 x 106 apoptotic cells 
fed to a constant number of DC, the percentage of CTCL cells expressing FoxP3 was 
1.45%, while a 10-fold increase in the apoptotic cell dose to 1.0 x 106 resulted in a 5.8-
fold increase to 8.41% of CD4+ T cells expressing FoxP3.  This dose-dependent increase 
in FoxP3 expression was not seen in the control group where increasing numbers of CD4-
treated viable CTCL cells were added to a constant number of DC.  Therefore, the 
generation of CTLA4+/FoxP3+ Treg cells may be controlled, to some degree, by the level 






Figure 4.  Dose-response curve of Treg induction in CTCL cells. 
     A.  Increasing numbers of apoptotic CTCL cells (0.3 x 106, 1.5 x 106, 3.0 x 106) were 
added to a constant number of DC (105), co-cultured overnight and used to stimulate 
freshly isolated CTCL cells.  As controls, increasing numbers of non-loaded DC were 
cultured with viable CTCL cells. Freshly isolated CTCL cells were then added and co-
cultured overnight.  The percentage of membrane CD3+/ cytoplasmic CTLA-4+ CTCL 
cells was measured by flow cytometry gated on the lymphocyte population.  B.  
Increasing numbers of apoptotic CTCL cells (0.10 x 106, 0.5 x 106, 1.0 x 106) were added 
to 105 DC and co-cultured overnight, followed by addition of 106 purified CTCL cells.  
The percentage of membrane CD4+/cytoplasmic FoxP3+ expressing cells was measured 










Treg CTCL cells suppress CD8-mediated perforin expression 
As the percentage of CTCL cells that were stimulated to adopt a Treg phenotype 
increased, the percentage of CD8+ T cells in co-culture expressing perforin, a granule that 
mediates CD8+ effector T cell cytotoxicity [44], inversely decreased (Fig 5).  The 
percentage of CD3+/CTLA4+ cells was increased from 4.88% to 18.6% (Fig. 5A) in the 
presence of DC loaded with increasing numbers of apoptotic cells. Concomitantly, there 
was a reduction in the percentage of cells co-expressing CD8/perforin, from 19.68% 
down to 9.87% at the highest dose of apoptotic cells used to load the DC.  Similarly, as 
the percentage of cells expressing CD4+/FoxP3+ increased from 1.45% to 8.41% (driven 
by a high dose of apoptotic cell DC loading), the percentage of CD8+ T cells expressing 
perforin dropped sharply from 36.69% to 5.58% (Fig. 5B), identifying a possible 
threshold of 1-1.5 x 106 apoptotic cells/105 DC required for induction of a Treg 
phenotype by the autologous DC.  Therefore, when CTCL cells are induced to adopt a 
Treg phenotype by co-culturing them with autologous DC that have ingested large 
numbers of apoptotic CTCL cells, they display the phenotypic characteristics of Treg, a 
conversion that may mediate the reduction in the percentage of CD8 T cells that express 







Figure 5.  Dose-dependent decrease in CD8-perforin expression as Treg cells increase.   
     A. As the percentage of membrane CD3+/cytoplasmic CTLA4+ cells increased there 
was an inversely related decrease in the number of membrane CD8+/cytoplasmic 
perforin+ cells. B. As the percentage of membrane CD4+/cytoplasmic FoxP3+ cells 
increased, there was an inversely related decrease in the number of membrane 










Expansion of CD8 T cell compartment following co-culture with autologous DC that 
have ingested low numbers of apoptotic cells 
We next sought to determine whether controlling the level of apoptotic T cells added to 
DC could shift the balance of suppression towards the generation of anti-tumor immunity 
by loading autologous DC with low numbers of apoptotic cells.  To do this, autologous 
DC were fed both a high number of apoptotic CTCL cells (above the demonstrated level 
of Treg induction) and a low number of apoptotic CTCL cells, and expansion of the CD8 
T cell population was monitored.  The percentage of CD8 T cells increased by 83% in the 
group of DC fed low numbers of apoptotic T cells (p≤0.042), as compared to control Day 
0 samples (Fig. 6A).  In addition, the absolute number of CD8 T cells recovered from 
overnight culture of column-passaged DC loaded with apoptotic CTCL cells also 
increased by 20% when compared to the initial Day 0 level of CD8 T cells (Fig. 6B).  
Expansion of the CD8 T cell compartment was greatest when DC were co-cultured with a 
lower number of apoptotic T cells, below the threshold for Treg induction, and this 
expanded CD8 T cell population might hold the potential to generate anti-tumor 






Figure 6.  Expansion of CD8 T cell compartment following co-culture with DC loaded 
with low numbers of apoptotic CTCL cells. 
     A.  Percentage of CD8+ T cells in co-culture increased significantly upon co-culture 
with autologous DC loaded with 0.25 x 106 apoptotic cells. B. The absolute number of 
CD8+ T cells increased upon co-culture with DC loaded with 0.25 x 106 apoptotic cells. 












Increased perforin activity and increased T cell death following loading of 
autologous DC with low numbers of apoptotic cells 
The expanded CD8 T cell compartment found when freshly purified CD8+ T cells were 
co-cultured with autologous DC that had been loaded with low numbers of apoptotic cells 
also demonstrated increased perforin activity.  The percentage of CD8+ T cells expressing 
perforin, the major cytotoxic granule by which effector CD8 cells mediate their anti-
tumor effects, rose from 8.4% (Fig 7A) to 13.8% (Fig 7B) when we lowered the dose of 
apoptotic cells fed to the DC.  This increase in perforin activity was not seen in the 
control population, where viable cells were co-incubated with autologous DC.  In 
addition, the increased perforin activity translated into significantly increased T cell death 
(p≤0.038) in the added CD3+ CTCL T cell population when CD8 T cells were co-cultured 
with low numbers of apoptotic cells and DC (Fig 7E).  Under these conditions, we found 
that 57% more CTCL cells were killed in comparison to the level of cell death obtained 
when DC were loaded with high numbers of apoptotic cells and used to prime CD8 T 
cells.   No significant change in CTCL cell death was noted when viable CTCL cells 
were added to the DC.  These results indicate that the expanded CD8 T cell population 
not only demonstrates increased perforin expression phenotypically, but is also 









 Figure 7.  Enhancement of CD8 T cell response upon exposure to autologous DC loaded 
with low numbers of apoptotic CTCL cells.   
     A - D. DC loaded with 1.0 x 106 and 0.25 x 106 apoptotic malignant T cells stimulated 
increased perforin activity in the CD8 T cell compartment, as compared to DC co-
cultured with 1.0 x 106 and 0.25 x 106 viable CTCL cells.  Results are presented as 
quadstats measuring the expression of membrane CD8/cytoplasmic perforin as 
determined by flow cytometric analysis of the gated lymphocyte population.  E. 
Increased perforin activity translated into increased CTCL cell death as measured by 
membrane CD3/cytoplasmic APO 2.7 staining.  Data analyzed using student’s t test.  NS 































The development of more effective DC-based immunotherapy has been hampered by a 
number of complicating factors, ranging from the length of culture necessary for DC 
development in vitro as well as from a lack of knowledge of the most appropriate stage of 
DC maturation required for effective anti-tumor vaccination [45]. In addition, the most 
appropriate antigen source for DC loading remains to be determined, with a variety of 
existing strategies including:  purified peptides [46]; tumor-targeted viral vectors [47]; 
tumor/DC hybrids; apoptotic whole tumor cells; and tumor lysates having been attempted 
and resulted in substantial variability in long-term clinical responses [48].   
      
Utilizing a magnetic bead column, we were able to generate potentially immunogenic DC 
in a fashion that offers several advantages over existing methodologies: 1) DC generated 
in this fashion can be obtained after a single overnight culture, far more rapidly than 
existing culture methods which can take up to 7 days; 2) Apoptotic whole cells are used 
as a source of tumor antigen, ensuring that the spectrum of CTCL antigenicity is 
incorporated into the DC instead of singular known antigens which may not be optimal or 
may be lost as the tumor de-differentiates; 3) Passage of monocytes through the column 
matrix induces the synchronized differentiation of a large population of monocytes into 
DC, allowing for the generation of a more robust source of APC displaying a spectrum of 
antigens upon re-injection; 4) The rapidity and ease of manipulating the cellular 
subpopulations of apoptotic CTCL cells and antigen-presenting cells allows the ability to 
easily optimize the cell populations and added factors in the hope of creating more 




In these experiments, we sought to further our understanding of the conditions that favor 
the induction of Treg cells following exposure to autologous DC co-cultured with large 
numbers of apoptotic CTCL cells.  The use of the magnetic bead column provides a new 
avenue for rapid generation of tumor-loaded DC because the variety of cellular 
components inherent in DC differentiation can be titrated to optimize dosing with this 
method.   
 
In our studies, CTCL cells were incubated with anti-CD3 antibody prior to passage 
through the magnetic bead column, rendering the antigen-experienced malignant T cells 
apoptotic, as had been previously demonstrated [38].  In addition, the use of anti-CD4 
antibody as a control allowed for separation of viable CD4+ CTCL cells to be used as a 
control population while at the same time not altering the CTCL cells in the control group.  
The membrane perturbation inherent in monocyte passage through the column matrix 
physically stimulates their transition into DC [49].  DC differentiation was measured by 
both the reduction of expression of the monocyte marker CD14 and the increased 
expression of class II and CD86.  In all instances, significant changes in the expression of 
these cell markers were found, indicating that the column passaged monocytes were 
differentiating into DC and that co-culture of the maturing DC with apoptotic malignant 
T cells further stimulated their entry into the DC pathway.  Differentiation of monocytes 
utilizing membrane stimulation, as in passage through the column matrix, is 
advantageous in particular in the setting of cancer immunotherapy since it has been 




priming phagocytosed peptides into the MHC class I pathway, which is crucial in 
generation of a CD8 anti-tumor response [49]. 
 
Following the generation of potentially immunogenic DC using the magnetic bead 
column, we sought to determine if Treg conversion could be induced.  By loading 
dendritic cells with large numbers of apoptotic cells, in a ratio of >10 apoptotic cells to 1 
DC, we were able to show that CTCL cells could be induced to assume some of the 
phenotypic and functional features of Treg cells.  These findings correlate with the work 
of Berger et al, who has shown that co-culture of freshly purified CTCL cells with 
autologous DC loaded with large numbers of apoptotic CTCL cells can induce a Treg 
profile in the responding CTCL cell population, one that has phenotypic and functional 
characteristics associated with Treg cells [10].  As described earlier, Treg are a subset of 
T cells that comprise 5-10% of the peripheral T cell population, and are involved in the 
maintenance of peripheral tolerance and prevention of autoimmune disease, regulating 
the response to infectious agents, transplanted tissues, and self antigens [29, 30, 50].  
Treg are characterized by their ability to suppress immune responses primarily by 
inhibiting normal T cell antigen driven proliferation [51, 52].  Treg have been found in 
increased numbers in solid tumors and are currently seen as one of the major hurdles to 
beneficial clinical responses in existing immunotherapies [53].  Removal of the 
suppressive Treg population has been shown to improve the outcome of cancer 
immunotherapy in both mouse models and clinical trials in a number of malignancies 





As the dose of apoptotic CTCL cells fed to a constant number of DC increased, 
expression of the Treg-associated markers CTLA-4, CD25, and FoxP3 also increased 
concomitantly.  In addition, there appeared to be a threshold ratio of apoptotic cell:DC 
that corresponded with induction of the Treg phenotype.  As the apoptotic cell:DC ratio 
increased from 5:1 to 10:1, expression of the hallmark of Treg cells, FoxP3, increased 
nearly four fold, indicating that perhaps there may be some internal DC checkpoint 
related to the number of processed apoptotic cells that governs the generation of an 
immune response versus a suppressive one.  While specific mechanisms of this process 
remain unclear, we can speculate that perhaps a CD8 T cell response is favored when low 
numbers of peptides are presented while induction of an immunosuppressive response 
requires a higher antigen burden and presentation of elevated levels of peptides in MHC 
class II.  In our experiments, the induced phenotypic Tregs also displayed some 
functional capabilities, as they were able to suppress CD8-mediated perforin expression 
in co-culture; an observation, which if borne out in vivo, may explain some of the failures 
in generating anti-tumor immunity with existing immunotherapies.  These findings are in 
concert with our previous studies which demonstrated that cultured CTCL cells can be 
stimulated to assume a Treg phenotype and function suppressing normal T cell driven 
immune responses when exposed to DC that have ingested apoptotic cells [4].  In our 
present studies, we demonstrate that, in addition, freshly isolated CTCL cells can be 
driven to adopt a Treg phenotype by overnight exposure to DC loaded with large 





By establishing that Treg cells could be rapidly generated using this method, we then 
sought to determine if that delicate balance between the DC and surrounding numbers of 
apoptotic cells could be shifted in the other direction, towards stimulating a more 
vigorous immune response.  By lowering the dose of apoptotic cells processed by a 
constant number of DC, we were able to induce significant expansion of the CD8 T cell 
compartment.  This expanded CD8 T cell compartment not only contained a greater 
percentage of perforin expressing cells but also mediated increased T cell death in the 
added CTCL cell population.  In terms of existing immunotherapies, these findings hold 
major clues into possible mechanisms for tumor survival following treatment.  If too 
aggressive an attempt is made at killing tumor cells in hopes of loading DC with large 
number of tumor antigens, it may lead to Treg generation and suppression of the desired 
immune response.  A considerable body of literature exists supporting the idea that the 
difference between the DC’s ability to induce tolerance or mediate immunity may be 
determined by its persistent exposure to antigen. [54, 55]  In our experiments, the DC that 
were exposed to larger numbers of apoptotic cells and hence had more persistent antigen 
exposure induced suppression of the CD8 T cell population.  These findings support 
earlier work and help to reinforce the role of apoptosis in the induction of 
immunosuppression. [28, 56]   
 
 A better understanding of the role of Treg cells in immunotherapy is crucial because 
while they hamper the effectiveness of cancer immunotherapy [53], Treg may be of great 
value for the therapy of autoimmune disease and transplantation tolerance. [30, 57]  The 




existing methodologies so that we can improve our understanding of apoptotic T cell and 
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